Denali Therapeutics
Market Cap
US$2.7b
Last Updated
2020/06/06 06:52 UTC
Data Sources
Company Financials +
Executive Summary
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -1.8% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has Denali Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DNLI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-6.8%
DNLI
-1.5%
US Biotechs
3.8%
US Market
1 Year Return
36.1%
DNLI
22.1%
US Biotechs
9.7%
US Market
Return vs Industry: DNLI exceeded the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: DNLI exceeded the US Market which returned 8.9% over the past year.
Shareholder returns
| DNLI | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.8% | -1.5% | 3.8% |
| 30 Day | 8.7% | 3.5% | 11.4% |
| 90 Day | 42.6% | 9.0% | 6.8% |
| 1 Year | 36.1%36.1% | 23.3%22.1% | 12.1%9.7% |
| 3 Year | n/a | 26.1%22.1% | 36.2%27.2% |
| 5 Year | n/a | -5.5%-11.0% | 63.7%45.4% |
Price Volatility Vs. Market
How volatile is Denali Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
The Denali Therapeutics (NASDAQ:DNLI) Share Price Has Gained 42% And Shareholders Are Hoping For More3 weeks ago | Simply Wall St
Denali Therapeutics Inc. (NASDAQ:DNLI) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year1 month ago | Simply Wall St
Does The Denali Therapeutics Inc. (NASDAQ:DNLI) Share Price Fall With The Market?Valuation
Is Denali Therapeutics undervalued compared to its fair value and its price relative to the market?
5.02x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DNLI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DNLI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DNLI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: DNLI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DNLI is overvalued based on its PB Ratio (5.2x) compared to the US Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Denali Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
-1.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNLI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNLI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNLI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNLI's revenue (44.2% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: DNLI's revenue (44.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNLI is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Denali Therapeutics performed over the past 5 years?
-23.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNLI is currently unprofitable.
Growing Profit Margin: DNLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNLI is unprofitable, and losses have increased over the past 5 years at a rate of -23.7% per year.
Accelerating Growth: Unable to compare DNLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: DNLI has a negative Return on Equity (-39.5%), as it is currently unprofitable.
Next Steps
Financial Health
How is Denali Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: DNLI's short term assets ($604.8M) exceed its short term liabilities ($47.6M).
Long Term Liabilities: DNLI's short term assets ($604.8M) exceed its long term liabilities ($102.9M).
Debt to Equity History and Analysis
Debt Level: DNLI is debt free.
Reducing Debt: DNLI has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNLI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DNLI has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 17.8% each year.
Next Steps
Dividend
What is Denali Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DNLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNLI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DNLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Ryan Watts (43yo)
4.83yrs
Tenure
US$4,978,607
Compensation
Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. si ...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD4.98M) is about average for companies of similar size in the US market ($USD5.84M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.83yrs | US$4.98m | 2.32% $63.6m | |
| Co-Founder | no data | US$2.48m | 0.59% $16.1m | |
| Co-Founder | no data | US$405.08k | 2.97% $81.4m | |
| CFO & Treasurer | 4.67yrs | US$2.53m | 0.95% $26.1m | |
| Chief Medical Officer & Head of Development | 5yrs | US$2.49m | 0.15% $4.0m | |
| Chief Technical and Manufacturing Officer | 1.83yrs | no data | no data | |
| Chief Scientific Officer | 0.58yr | no data | no data | |
| Vice President of Legal | 1.42yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Head of Biology Discovery | no data | no data | no data |
3.3yrs
Average Tenure
46yo
Average Age
Experienced Management: DNLI's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.83yrs | US$4.98m | 2.32% $63.6m | |
| Co-Founder | no data | US$405.08k | 2.97% $81.4m | |
| Independent Director | 5.08yrs | US$395.08k | 0.0019% $52.6k | |
| Independent Chairperson | 3.83yrs | US$428.08k | 0.13% $3.6m | |
| Independent Director | 5.17yrs | US$402.58k | 0.31% $8.4m | |
| Independent Director | 5.17yrs | US$404.08k | 0.31% $8.4m | |
| Independent Director | 2.25yrs | US$405.08k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.08yrs | US$402.58k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.1yrs
Average Tenure
59yo
Average Age
Experienced Board: DNLI's board of directors are considered experienced (5.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DNLI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Top Shareholders
Company Information
Denali Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Denali Therapeutics Inc.
- Ticker: DNLI
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.738b
- Shares outstanding: 105.61m
- Website: https://www.denalitherapeutics.com
Number of Employees
Location
- Denali Therapeutics Inc.
- 161 Oyster Point Boulevard
- 2nd Floor
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4DN | MUN (Boerse Muenchen) | Yes | Common Stock | DE | EUR | Dec 2017 |
| DNLI | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Dec 2017 |
| 4DN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2017 |
Biography
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 06:52 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.